Karimi, Y., Abrisqueta, P., Andreadis, C., Cheah, C., Darrah, J., Vos, S. D., Falchi, L., Musuraca, G., Trneny, M., Sureda, A., Kearns, C., Archer, K. G., Geybels, M., Risum, M., Ukropec, J., Atiya, M. E., Córdoba, R. (2026). Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7061